These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

118 related items for PubMed ID: 16266862

  • 1. Changes in metalloproteinases in healthy normotensive patients with high-normal blood pressure.
    Papadopoulos DP, Makris TK, Krespi PG, Poulakou M, Papazachou OG, Hatzizacharias AN, Perrea D, Votteas V.
    Eur Cytokine Netw; 2005 Sep; 16(3):211-4. PubMed ID: 16266862
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Antiendothelial cell antibody levels in healthy normotensives with high normal blood pressure.
    Papadopoulos DP, Makris TK, Krespi P, Papazachou U, Stavroulakis G, Hatzizacharias A, Votteas V.
    Clin Exp Hypertens; 2006 Nov; 28(8):663-7. PubMed ID: 17132533
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Elevated matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 in obese children and adolescents.
    Głowińska-Olszewska B, Urban M.
    Metabolism; 2007 Jun; 56(6):799-805. PubMed ID: 17512313
    [Abstract] [Full Text] [Related]

  • 7. Changes of metalloproteinases profile in patients with masked hypertension.
    Papadopoulos DP, Thomopoulos C, Perrea D, Papazachou U, Daskalaki M, Bourantas C, Votteas V, Makris TK.
    Angiology; 2007 Jun; 60(6):757-62. PubMed ID: 19114409
    [Abstract] [Full Text] [Related]

  • 8. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease.
    Ahmed SH, Clark LL, Pennington WR, Webb CS, Bonnema DD, Leonardi AH, McClure CD, Spinale FG, Zile MR.
    Circulation; 2006 May 02; 113(17):2089-96. PubMed ID: 16636176
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Impact of the metalloproteinase-9/tissue inhibitor of metalloproteinase-1 system on large arterial stiffness in patients with essential hypertension.
    Tan J, Hua Q, Xing X, Wen J, Liu R, Yang Z.
    Hypertens Res; 2007 Oct 02; 30(10):959-63. PubMed ID: 18049028
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Assessment of matrix metalloproteinase (MMP)-2, MMP-8, MMP-9, and their inhibitors, the tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in obese children and adolescents.
    Belo VA, Souza-Costa DC, Lana CM, Caputo FL, Marcaccini AM, Gerlach RF, Bastos MG, Tanus-Santos JE.
    Clin Biochem; 2009 Jul 02; 42(10-11):984-90. PubMed ID: 19358835
    [Abstract] [Full Text] [Related]

  • 13. Alterations in peripheral blood levels of TIMP-1, MMP-2, and MMP-9 in patients with type-2 diabetes.
    Lee SW, Song KE, Shin DS, Ahn SM, Ha ES, Kim DJ, Nam MS, Lee KW.
    Diabetes Res Clin Pract; 2005 Aug 02; 69(2):175-9. PubMed ID: 16005367
    [Abstract] [Full Text] [Related]

  • 14. Matrix metalloproteinases 2 and 9 and their tissue inhibitors 1 and 2 in premenopausal obese women: relationship to cardiac function.
    Kosmala W, Plaksej R, Przewlocka-Kosmala M, Kuliczkowska-Plaksej J, Bednarek-Tupikowska G, Mazurek W.
    Int J Obes (Lond); 2008 May 02; 32(5):763-71. PubMed ID: 18197181
    [Abstract] [Full Text] [Related]

  • 15. Specific changes in plasma concentrations of matrix metalloproteinase-2 and -9, TIMP-1 and TGF-beta1 in patients with distinct types of primary glomerulonephritis.
    Bauvois B, Mothu N, Nguyen J, Nguyen-Khoa T, Nöel LH, Jungers P.
    Nephrol Dial Transplant; 2007 Apr 02; 22(4):1115-22. PubMed ID: 17205957
    [Abstract] [Full Text] [Related]

  • 16. Matrix-metalloproteinases and their inhibitors are elevated in severe sepsis: prognostic value of TIMP-1 in severe sepsis.
    Hoffmann U, Bertsch T, Dvortsak E, Liebetrau C, Lang S, Liebe V, Huhle G, Borggrefe M, Brueckmann M.
    Scand J Infect Dis; 2006 Apr 02; 38(10):867-72. PubMed ID: 17008230
    [Abstract] [Full Text] [Related]

  • 17. Increased circulating levels of matrix metalloproteinase (MMP)-8, MMP-9, and pro-inflammatory markers in patients with metabolic syndrome.
    Gonçalves FM, Jacob-Ferreira AL, Gomes VA, Casella-Filho A, Chagas AC, Marcaccini AM, Gerlach RF, Tanus-Santos JE.
    Clin Chim Acta; 2009 May 02; 403(1-2):173-7. PubMed ID: 19254704
    [Abstract] [Full Text] [Related]

  • 18. Matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in patients with relapsing-remitting multiple sclerosis treated with interferon beta.
    Boz C, Ozmenoglu M, Velioglu S, Kilinc K, Orem A, Alioglu Z, Altunayoglu V.
    Clin Neurol Neurosurg; 2006 Feb 02; 108(2):124-8. PubMed ID: 16412833
    [Abstract] [Full Text] [Related]

  • 19. Clinical significance of matrix metalloproteinases activity in acute myocardial infarction.
    Papadopoulos DP, Moyssakis I, Makris TK, Poulakou M, Stavroulakis G, Perrea D, Votteas VE.
    Eur Cytokine Netw; 2005 Jun 02; 16(2):152-60. PubMed ID: 15941687
    [Abstract] [Full Text] [Related]

  • 20. Matrix metalloproteinases in isolated hypercholesterolemia.
    Malik J, Stulc T, Ceska R.
    Int Angiol; 2005 Sep 02; 24(3):300-3. PubMed ID: 16158043
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.